| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.21 | 4e-06 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.24 | 4e-06 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.2 | 1e-05 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.21 | 2e-05 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-05 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.2 | 2e-05 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.29 | 4e-05 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-05 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.29 | 6e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.17 | 7e-05 |